Nuvation Bio (NUVB) CSO Gary Hattersley Exercises Options, Sells Shares

What Happened
Gary Hattersley, Chief Scientific Officer of Nuvation Bio (NUVB), exercised 100,000 stock options (paid $1.87/share, $187,000 total) on August 19, 2026 and sold 100,000 shares in an open-market sale the same day for a weighted-average price of $7.09/share (total proceeds ≈ $709,240). The filing also shows a derivative disposition related to the option exercise (reported with $0 proceeds), reflecting the conversion/settlement of the option.

Key Details

• Transaction date: August 19, 2026. Form filed August 21, 2026 (timely).
• Option exercise (code M): 100,000 shares acquired at $1.87 each = $187,000.
• Open-market sale (code S): 100,000 shares sold at weighted-average $7.09 = $709,240; sale prices ranged $7.02–$7.21. (Reporting person can provide per-price breakdown on request.)
• Footnote: Sales were made pursuant to a 10b5-1 plan dated December 4, 2025.
• Vesting note: Options vest 25% one year after February 29, 2024, then monthly over 36 months (subject to continued service).
• Shares owned after the transactions: not specified in the details you provided—see the full Form 4 for post-transaction beneficial ownership.

Context
This was an option exercise followed by an immediate sale of the resulting shares (a common practice to cover exercise cost/taxes or to realize gains). The 10b5-1 plan indicates the sales were pre-arranged, which is routine and may limit inference about near-term insider sentiment. All items above are factual disclosures from the Form 4.